WELCOME MESSAGE
On behalf of the congress committees, it si with great pleasure to announce that the 19th International Congress of Psychiatry, and the 7 International Congress of Child and Adoles-cent Psychiatry, wil be held from 11-13 June, 2024.
Our Theme is Resistant Psychiatric Disorders Predictors and Challenges Treatment resistance affects 60% of patients with psychiatric disorders; and is associated with increased healthcare burden and costs up to ten-fold higher. There has been recent increase in the proportion of psychiatric research focusing on treatment resistance, its prevalence and impact. In this congress we wil provide an overview of treatment resistance, considering its con- ceptualisation, assessment, epidemiology, impact, and common neurobiological models. It is important to review new treatments and consensus guidelines, covering schizophrenia, major depressive disorder, bipolar affective disorder, and obsessive compulsive disorder (OCD). Rec- ommendations to address these issues, including harmonisation of definitions, and research into the mechanisms and novel interventions to enable targeted and personalised therapeutic ap-proaches would be achieved by your valuable sharing and exchange experiences.
Make your plans and arrangements to join us in this hallmark event. Meet our Eminent Speakers, National, Regional and International Waiting to welcoming you in the congress.
On behalf of the congress committees, it si with great pleasure to announce that the 19th International Congress of Psychiatry, and the 7 International Congress of Child and Adoles-cent Psychiatry, wil be held from 11-13 June, 2024.
Our Theme is Resistant Psychiatric Disorders Predictors and Challenges Treatment resistance affects 60% of patients with psychiatric disorders; and is associated with increased healthcare burden and costs up to ten-fold higher. There has been recent increase in the proportion of psychiatric research focusing on treatment resistance, its prevalence and impact. In this congress we wil provide an overview of treatment resistance, considering its con- ceptualisation, assessment, epidemiology, impact, and common neurobiological models. It is important to review new treatments and consensus guidelines, covering schizophrenia, major depressive disorder, bipolar affective disorder, and obsessive compulsive disorder (OCD). Rec- ommendations to address these issues, including harmonisation of definitions, and research into the mechanisms and novel interventions to enable targeted and personalised therapeutic ap-proaches would be achieved by your valuable sharing and exchange experiences.
Make your plans and arrangements to join us in this hallmark event. Meet our Eminent Speakers, National, Regional and International Waiting to welcoming you in the congress.
